Short-term outcome and predictors of therapeutic effects of intradiscal condoliase injection for patients with lumbar disc herniation

Introduction Intradiscal chondroitin sulfate ABC endolyase (condoliase) injection for lumbar disc herniation (LDH) is an intermediate between conservative treatment and surgery. This approach can only be performed once in a lifetime; therefore, understanding the factors that determine the indication for the use of condoliase and predict outcomes is important. The aim of this study was to review clinical and imaging findings in patients after intradiscal condoliase injection, and to assess the short-term outcomes and factors associated with therapeutic effects. Methods The subjects were 42 patients with LDH who underwent intradiscal condoliase injection. Patients with and without a ≥50% improvement from baseline of leg pain at 3 months after injection were defined as responders and non-responders, respectively. Clinical features and radiological findings were compared between these groups. Results Of the 42 patients, 32 (76.2%) were responders and 10 (23.8%) were non-responders. Of 8 patients with a history of discectomy at the same level as LDH, 6 (75.0%) were responders. Non-responders had a significantly longer time from onset to treatment, smaller herniated volume before treatment, lower percentage reduction of herniated mass, and less intervertebral disc degeneration before treatment. There were no significant differences in LDH types (subligamentous extrusion or transligamentous extrusion types), high-intensity area within the herniation, changes in disc height, and region of condoliase injection between the two groups. Conclusions Intradiscal condoliase injection had a good short-term therapeutic effect in patients with LDH, including in transligamentous extrusion-type and revision cases as well as subligamentous extrusion-type cases. Administration of intradiscal condoliase injection may be most effective in patients with a larger herniated mass volume before treatment, and least effective in cases with a longer time and less intervertebral disc degeneration before treatment.